Celldex Therapeutics Inc. (NASDAQ:CLDX) – Investment analysts at Roth Capital increased their FY2016 EPS estimates for shares of Celldex Therapeutics in a report released on Monday. Roth Capital analyst J. Pantginis now forecasts that the firm will post earnings of ($1.26) per share for the year, up from their prior estimate of ($1.32). Roth Capital has a “Buy” rating and a $7.00 price objective on the stock. Roth Capital also issued estimates for Celldex Therapeutics’ Q4 2016 earnings at ($0.30) EPS, FY2017 earnings at ($1.30) EPS, FY2018 earnings at ($1.31) EPS and FY2019 earnings at ($1.38) EPS.

A number of other brokerages have also recently issued reports on CLDX. Wedbush reissued a “neutral” rating and issued a $3.00 target price on shares of Celldex Therapeutics in a report on Tuesday, August 9th. Jefferies Group raised their target price on shares of Celldex Therapeutics to $5.00 and gave the stock a “hold” rating in a report on Friday, August 5th. Cantor Fitzgerald reissued a “buy” rating and issued a $9.00 target price on shares of Celldex Therapeutics in a report on Monday, October 10th. Zacks Investment Research raised shares of Celldex Therapeutics from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a report on Thursday. Finally, Brean Capital began coverage on shares of Celldex Therapeutics in a report on Tuesday, October 4th. They issued a “buy” rating and a $16.00 target price on the stock. Five analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $7.39.

Earnings History and Estimates for Celldex Therapeutics (NASDAQ:CLDX)

Shares of Celldex Therapeutics (NASDAQ:CLDX) opened at 4.17 on Thursday. The firm’s market cap is $419.27 million. Celldex Therapeutics has a 12-month low of $2.85 and a 12-month high of $18.62. The company has a 50 day moving average price of $3.64 and a 200-day moving average price of $4.04.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04. The business had revenue of $2.20 million for the quarter, compared to analysts’ expectations of $1.09 million. Celldex Therapeutics had a negative return on equity of 51.46% and a negative net margin of 1,923.41%. The company’s revenue was up 115.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.32) EPS.

A number of large investors have recently made changes to their positions in CLDX. JPMorgan Chase & Co. boosted its stake in shares of Celldex Therapeutics by 94.9% in the first quarter. JPMorgan Chase & Co. now owns 690,128 shares of the biopharmaceutical company’s stock valued at $2,608,000 after buying an additional 336,049 shares during the last quarter. National Planning Corp boosted its stake in shares of Celldex Therapeutics by 3.1% in the second quarter. National Planning Corp now owns 55,246 shares of the biopharmaceutical company’s stock valued at $251,000 after buying an additional 1,650 shares during the last quarter. Canada Pension Plan Investment Board boosted its stake in shares of Celldex Therapeutics by 304.5% in the first quarter. Canada Pension Plan Investment Board now owns 44,900 shares of the biopharmaceutical company’s stock valued at $170,000 after buying an additional 33,800 shares during the last quarter. Bellevue Group AG purchased a new stake in shares of Celldex Therapeutics during the first quarter valued at approximately $605,000. Finally, Alps Advisors Inc. boosted its stake in shares of Celldex Therapeutics by 24.9% in the second quarter. Alps Advisors Inc. now owns 138,680 shares of the biopharmaceutical company’s stock valued at $609,000 after buying an additional 27,677 shares during the last quarter. 78.41% of the stock is currently owned by hedge funds and other institutional investors.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (rindopepimut and CDX-110) is a therapeutic vaccine in clinical studies for the treatment of glioblastoma patients that express a specific cancer marker known as type III epidermal growth factor receptor mutation (EGFRvIII).

5 Day Chart for NASDAQ:CLDX

Receive News & Stock Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related stocks with our FREE daily email newsletter.